277 related articles for article (PubMed ID: 27561602)
21. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
[TBL] [Abstract][Full Text] [Related]
22. Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance.
Wolf S; Lorenz J; Mössner J; Wiedmann M
World J Gastroenterol; 2010 Jan; 16(2):156-66. PubMed ID: 20066734
[TBL] [Abstract][Full Text] [Related]
23. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
Dong S; Qu X; Li W; Zhong X; Li P; Yang S; Chen X; Shao M; Zhang L
J Hematol Oncol; 2015 Apr; 8():43. PubMed ID: 25925741
[TBL] [Abstract][Full Text] [Related]
24. Design, characterization, and in vitro antiproliferative efficacy of gemcitabine conjugates based on carboxymethyl glucan.
Ma L; Chen Y; Wang X; Xiong M; Sun Y; Zhang X; Zhao Y
Bioorg Med Chem Lett; 2018 Sep; 28(17):2920-2924. PubMed ID: 30017318
[TBL] [Abstract][Full Text] [Related]
25. IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy.
Ferté C; Loriot Y; Clémenson C; Commo F; Gombos A; Bibault JE; Fumagalli I; Hamama S; Auger N; Lahon B; Chargari C; Calderaro J; Soria JC; Deutsch E
Mol Cancer Ther; 2013 Jul; 12(7):1213-22. PubMed ID: 23640142
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and in vitro anticancer activity of new gemcitabine-nucleoside analogue dimers containing methyltriazole or ester-methyltriazole linker.
Trznadel R; Singh A; Kleczewska N; Liberska J; Ruszkowski P; Celewicz L
Bioorg Med Chem Lett; 2019 Sep; 29(18):2587-2594. PubMed ID: 31400940
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of a novel hexavalent humanized anti-IGF-1R antibody and its bivalent parental IgG in diverse cancer cell lines.
Chang CH; Wang Y; Trisal P; Li R; Rossi DL; Nair A; Gupta P; Losman M; Cardillo TM; Rossi EA; Goldenberg DM
PLoS One; 2012; 7(8):e44235. PubMed ID: 22952934
[TBL] [Abstract][Full Text] [Related]
28. The novel IGF-IR/Akt-dependent anticancer activities of glucosamine.
Song KH; Kang JH; Woo JK; Nam JS; Min HY; Lee HY; Kim SY; Oh SH
BMC Cancer; 2014 Jan; 14():31. PubMed ID: 24438088
[TBL] [Abstract][Full Text] [Related]
29. High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507).
Gong Y; Yao E; Shen R; Goel A; Arcila M; Teruya-Feldstein J; Zakowski MF; Frankel S; Peifer M; Thomas RK; Ladanyi M; Pao W
PLoS One; 2009 Oct; 4(10):e7273. PubMed ID: 19806209
[TBL] [Abstract][Full Text] [Related]
30. Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor.
McCaffery I; Tudor Y; Deng H; Tang R; Suzuki S; Badola S; Kindler HL; Fuchs CS; Loh E; Patterson SD; Chen L; Gansert JL
Clin Cancer Res; 2013 Aug; 19(15):4282-9. PubMed ID: 23741071
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, and evaluation of liver-specific gemcitabine prodrugs for potential treatment of hepatitis C virus infection and hepatocellular carcinoma.
Stephenson AA; Cao S; Taggart DJ; Vyavahare VP; Suo Z
Eur J Med Chem; 2021 Mar; 213():113135. PubMed ID: 33454548
[TBL] [Abstract][Full Text] [Related]
32. Regioselective chemical and rapid enzymatic synthesis of a novel redox – Antiproliferative molecular hybrid.
Geromichalou E; Sayyad N; Kyriakou E; Chatzikonstantinou AV; Giannopoulou E; Vrbjar N; Kalofonos HP; Stamatis H; Tzakos AG
Eur J Med Chem; 2015; 96():47-57. PubMed ID: 25874330
[TBL] [Abstract][Full Text] [Related]
33. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity.
Dong J; Sereno A; Aivazian D; Langley E; Miller BR; Snyder WB; Chan E; Cantele M; Morena R; Joseph IB; Boccia A; Virata C; Gamez J; Yco G; Favis M; Wu X; Graff CP; Wang Q; Rohde E; Rennard R; Berquist L; Huang F; Zhang Y; Gao SX; Ho SN; Demarest SJ; Reff ME; Hariharan K; Glaser SM
MAbs; 2011; 3(3):273-88. PubMed ID: 21393993
[TBL] [Abstract][Full Text] [Related]
34. Self-assembling, amphiphilic polymer-gemcitabine conjugate shows enhanced antitumor efficacy against human pancreatic adenocarcinoma.
Chitkara D; Mittal A; Behrman SW; Kumar N; Mahato RI
Bioconjug Chem; 2013 Jul; 24(7):1161-73. PubMed ID: 23758084
[TBL] [Abstract][Full Text] [Related]
35. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
Denlinger CE; Rundall BK; Keller MD; Jones DR
Ann Thorac Surg; 2004 Oct; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
[TBL] [Abstract][Full Text] [Related]
36. Safety, tolerability, pharmacokinetics and antitumor activity of ganitumab, an investigational fully human monoclonal antibody to insulin-like growth factor type 1 receptor, combined with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer: a phase 1b study.
Okusaka T; Ikeda M; Fukutomi A; Kobayashi Y; Shibayama K; Takubo T; Gansert J
Jpn J Clin Oncol; 2014 May; 44(5):442-7. PubMed ID: 24782485
[TBL] [Abstract][Full Text] [Related]
37. A humanized anti-IGF-1R monoclonal antibody (R1507) and/or metformin enhance gemcitabine-induced apoptosis in pancreatic cancer cells.
Kawanami T; Takiguchi S; Ikeda N; Funakoshi A
Oncol Rep; 2012 Mar; 27(3):867-72. PubMed ID: 22200743
[TBL] [Abstract][Full Text] [Related]
38. Combination of DN604 with gemcitabine led to cell apoptosis and cell motility inhibition via p38 MAPK signaling pathway in NSCLC.
Wang X; Chen F; Gou S
Bioorg Chem; 2020 Nov; 104():104234. PubMed ID: 32920359
[TBL] [Abstract][Full Text] [Related]
39. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.
Yeh J; Litz J; Hauck P; Ludwig DL; Krystal GW
Lung Cancer; 2008 May; 60(2):166-74. PubMed ID: 18006183
[TBL] [Abstract][Full Text] [Related]
40. Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.
Macaulay VM; Middleton MR; Protheroe AS; Tolcher A; Dieras V; Sessa C; Bahleda R; Blay JY; LoRusso P; Mery-Mignard D; Soria JC
Ann Oncol; 2013 Mar; 24(3):784-91. PubMed ID: 23104723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
